Navigation Links
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
Date:2/4/2010

S for the development of peramivir for patients hospitalized with influenza also increased as two global Phase 3 studies were initiated.  These increases in revenues were offset by lower amortization of deferred revenue from collaborations.  Specifically, $26.5 million of previously deferred revenue related to the termination of the Company's collaboration with Roche was recognized during the fourth quarter of 2008.

Research and development (R&D) expenses increased to $31.6 million for the fourth quarter of 2009 from $22.1 million in the prior year period.  The higher R&D expenses resulted from an increase in clinical development costs associated with our peramivir program and an increase in manufacturing costs as the Company completed the production of approximately 130,000 courses of peramivir.  In addition, clinical development costs increased during the current quarter as the Company initiated a Phase 2 study of BCX4208 for the treatment of gout.  These increases were offset by reductions in clinical development and manufacturing costs for the forodesine program.  During the fourth quarter 2008, the Company recognized $8.2 million of previously deferred expense from the termination of its collaboration with Roche.

General and administrative (G&A) expenses increased to $3.6 million for the fourth quarter of 2009 from $2.4 million for the fourth quarter of 2008, primarily due to increases in legal and consulting fees.

Interest income for the three months ended December 31, 2009 was $0.1 million as compared to $0.3 million for the same period of last year.  The decrease was driven by a lower average cash and secur
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
2. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
3. BioCryst Announces Pricing of Public Offering of Common Stock
4. BioCryst to Present at Oppenheimer Healthcare Conference
5. Emergency Use Authorization Granted For BioCrysts Peramivir
6. BioCryst to Present at JMP Securities Healthcare Conference
7. BioCryst Clarifies Government Declaration Regarding Peramivir
8. BioCryst Provides Update Regarding Peramivir for Influenza
9. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
10. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
11. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 Decision Resources ... (AD) therapies will more than triple, reaching nearly ... forecasted launch of the first disease-modifying therapies (DMTs), ... these novel premium-priced agents—which include the anti-beta-amyloid monoclonal ... well as the BACE inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
(Date:7/21/2014)...  PowerVision, Inc., a medical device company developing ... announced that Douglas D. Koch , M.D., ... and Professor of Ophthalmology, at Baylor College of ... As a recipient of several ... Lifetime Achievement award, Koch will join the distinguished ...
Breaking Medicine Technology:The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 2The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4
... 13, 2011  GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based ... fight Human Immunodeficiency Virus (HIV) infections, announced that the ... clinical trial for the Company,s HIV/AIDS therapeutic vaccine.  This ... the treatment of persons who are HIV infected. ...
... Masimo (NASDAQ: MASI ) ... Acoustic Respiration Rate (RRa™) was presented at the ... Graduate Assembly (PGA) Meeting in New York City. ... the positive clinical outcomes and patient safety impact of Masimo,s ...
Cached Medicine Technology:GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 2GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 2New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 4New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 5
(Date:7/22/2014)... Hope For The Warriors® is excited to ... staff. This addition comes in tandem with new office ... The Warriors® is a national nonprofit organization that assists ... the fallen who have sustained physical and psychological wounds ... will support programs within Career Transition & Education. He ...
(Date:7/22/2014)... Garland’s new Energizer BK ... used as a flood coat over new and existing ... premium restoration material. It provides natural resistance to moisture, ... reducing life-cycle costs. Energizer BK is specially formulated with ... resistance in addition to superior strength and flexibility. ...
(Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
(Date:7/21/2014)... fastest-growing high school sports in the United States, with ... game. The growing participation numbers, however, mean that more ... in lacrosse practice and competition. , In a study ... Sports Medicine and available in an upcoming print ... Policy at Nationwide Children,s Hospital and the Colorado School ...
(Date:7/21/2014)... As reported by CBS Local Pittsburgh in the article ... (7/15), thrill-seeking participants raised $100,000 to raise drug abuse ... Philly. 100 people, including some well-known local news reporters, ... Hotel. Some of the participants shared stories of their ... son killed himself after a long battle with addiction. ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3
... --MinuteClinic Provides Quality and Convenience Close to Home and the ... ... Alliance With Integris Health--, OKLAHOMA CITY, Sept. 7 Quick, convenient, ... opening of a,MinuteClinic health care center at the CVS/pharmacy store in Moore ...
... pulmonary embolisma potential life-threatening blockage in a lung arteryshould ... than a CT (computed tomography) angiogram, conclude authors in ... Medicine. , A V/Q scan can be the first ... a pulmonary embolism, noted H. Dirk Sostman, a professor ...
... School at the University of Warwick reveals that womens health ... , The researchers looked at men and women sleeping ... see if their risk of having hypertension was any higher ... more of sleep a night. Among other problems increased hypertension ...
... Blue Shield in Indiana for its Members, INDIANAPOLIS, ... and,M-Plan, Inc., an Indiana-based managed care organization, announced today,that ... of Indiana as,the insurer of choice for its members ... WellPoint and M-Plan have entered into an,agreement that ensures ...
... KING OF PRUSSIA, PA, Sept. 7 /PRNewswire-FirstCall/ - ... discovery and development,solutions, has won the Good Clinical ... that best promotes access to new medicines. This,award ... awards introduced this year to,recognize excellence in clinical ...
... N.J., Sept. 6 Wyeth (NYSE: WYE ... that the United States,District Court for the District ... a preliminary injunction against Teva Pharmaceuticals USA, Inc.,and ... of a generic,version of PROTONIX(R) (pantoprazole sodium) prior ...
Cached Medicine News:Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 2Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 4Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 5Health News:Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 3Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Wyeth and Nycomed Announce Court Denial of Preliminary Injunction 2Health News:Wyeth and Nycomed Announce Court Denial of Preliminary Injunction 3
... At the heart of the innovative ... EU-M60, delivering excellent imaging performance to meet ... Together with the new GF-UM160 ultrasonic gastrovideoscope, ... penetration to view organs deeper in the ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
Total T3 EIA Thyroid Function 025-BC-1005...
Medicine Products: